Press Release
Daré Bioscience to Present at the 2019 BIO International Convention
The theme for the 2019
“Given our focus on identifying development and global commercialization partners for our portfolio of women’s health product candidates, we are pleased to have the opportunity to present and participate in the partnering meetings organized by the conference,” said
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s sexual health, vaginal health, fertility, and contraception. The company’s mission is to identify, develop and bring to market a portfolio of novel, differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women in these targeted areas.
Daré’s product portfolio includes potential first-in-category candidates in clinical development: Ovaprene®, a non-hormonal, monthly contraceptive vaginal ring; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause. To learn more about Daré’s full portfolio of women’s health product candidates, and mission to deliver novel therapies for women, please visit www.darebioscience.com.
Daré may announce material information about its finances, product candidates, clinical trials and other matters using its investor relations website (http://ir.darebioscience.com),
Contacts:
Investors on behalf of Daré
Burns McClellan
agray@burnsmc.com
212-213-0006
OR
Media on behalf of Daré
Canale Communications
Jordann@canalecomm.com
619-849-6009
Source: Daré Bioscience
Source: Dare Bioscience, Inc.